NCT02964611

Brief Summary

The aim of this study is to compare personality and social cognition changes, including emotion detection and self-awareness, and neuroanatomical correlates in patients, and how that affects the caregiver-patient relationship.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2013

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2013

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 16, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 16, 2016

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

September 23, 2016

Completed
2 months until next milestone

First Posted

Study publicly available on registry

November 16, 2016

Completed
Last Updated

December 18, 2024

Status Verified

April 1, 2019

Enrollment Period

3.6 years

First QC Date

September 23, 2016

Last Update Submit

December 13, 2024

Conditions

Outcome Measures

Primary Outcomes (14)

  • Personality via the Interpersonal Adjectives Scales and differences between AD, PD, and FTLD

    Assesses interpersonal aspects of personality

    one time visit, through study completion of 3 years

  • Personality via the Behaviour Inhibition/Approach Scale (BIS/BAS) and differences between AD, PD, and FTLD

    Assesses the behavioural approach system that regulates appetitive motives, in which the goal is to move toward something desired, and the behavioural avoidance (or inhibition) system that regulates aversive motives, in which the goal is to move away from something unpleasant

    one time visit, through study completion of 3 years

  • Personality via the Big Five Inventory (BFI) and differences between AD, PD, and FTLD

    Assesses the patient's Big Five dimensions (openness, conscientiousness, extraversion, agreeableness, and neuroticism) with respect to past and current behavior

    one time visit, through study completion of 3 years

  • Social cognition via Social Norms Questionnaire and differences between AD, PD, and FTLD

    Assesses the patient's understanding of culturally relevant social norms

    one time visit, through study completion of 3 years

  • Social cognition via Interpersonal Reactivity Index (IRI) and differences between AD, PD, and FTLD

    Assesses the patient's empathy or ability to share in another's mental and emotional experience

    one time visit, through study completion of 3 years

  • Social cognition via Revised Self-Monitoring Scale (RSMS) and differences between AD, PD, and FTLD

    Assesses the patient's sensitivity to the expressive behaviour of others and their ability to monitor their self-presentation

    one time visit, through study completion of 3 years

  • Social cognition via Social Behaviour Observer Checklist and differences between AD, PD, and FTLD

    Assesses behaviors specific to behavioural variant Frontotemporal Dementia (bvFTD) and is helpful in differentiating bvFTD versus Alzheimer's disease.

    one time visit, through study completion of 3 years

  • Neuropsychiatric Inventory (NPI) and differences between AD, PD, and FTLD

    Assesses 12 neuropsychiatric disturbances commonly encountered in patients with dementia, including: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behaviour, night-time behaviour disturbances, and appetite and eating abnormalities

    one time visit, through study completion of 3 years

  • Clinical Dementia Rating Scale (CDR) and differences between AD, PD, and FTLD

    Assesses 8 domains of global dementia, including: memory, orientation, judgment/problem solving, community affairs, home and hobbies, personal care, behavioural comportment and personality, and language

    one time visit, through study completion of 3 years

  • Functional Activities Questionnaire (FAQ) and differences between AD, PD, and FTLD

    Assesses functional capacity in older adults

    one time visit, through study completion of 3 years

  • Behavioural Tests composite score and differences between AD, PD, and FTLD

    Orientation, Digit span backward and forward, Naming, Modified trails, Benson figure copy, Cerad, Clock draw

    one time visit, through study completion of 3 years

  • Emotion Evaluation Task (EET) portion of The Awareness of Social Inference Test and differences between AD, PD, and FTLD

    Assesses the recognition of six basic emotions commonly recognized across cultures (happiness, sadness, anger, surprise, disgust, fear) as well as a seventh "neutral" emotion. The emotions are presented via video vignettes. After viewing each scene, the patient will be asked to choose the emotion represented from a list of seven emotional categories. The caregiver will complete the test separately, and be asked both to guess the emotion in each vignette, and to speculate on which emotion the patient will guess.

    one time visit, through study completion of 3 years

  • Geriatric Depression Scale (GDS) and differences between AD, PD, and FTLD

    Assesses mood and depression in geriatric patients

    one time visit, through study completion of 3 years

  • Neuroimaging and differences between AD, PD, and FTLD

    Functional connectivity of networks associated with social cognition and personality

    one time visit, through study completion of 3 years

Study Arms (4)

Alzheimer's disease

Observational Study

Behavioral: Observational Study

Parkinson's disease

Observational Study

Behavioral: Observational Study

Frontotemporal Lobar Degeneration

Observational Study

Behavioral: Observational Study

Healthy Controls

Observational Study

Behavioral: Observational Study

Interventions

This is an observational study.

Alzheimer's diseaseFrontotemporal Lobar DegenerationHealthy ControlsParkinson's disease

Eligibility Criteria

Age50 Years - 90 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with a diagnosis of Alzheimer's disease, Parkinson's disease or Frontotemporal Lobar Degeneration

You may qualify if:

  • Patients:
  • ability to speak and understand the English language (as questionnaires and tests are only available in English)
  • Caregivers:
  • primary caregiver for a given patient
  • ability to speak and understand the English language (as questionnaires and tests are only available in English)

You may not qualify if:

  • Patients and Caregivers:
  • history of another neurological disorder
  • psychiatric disorder
  • severe aphasia (semantic word loss)
  • visual deficits requiring correction beyond the use of eyeglasses or contact lenses (intact visual acuity is required for completing both the questionnaires and the emotion evaluation test which consists of video vignettes)
  • auditory deficits requiring correction beyond hearing aids (videos have auditory component)
  • Patients:
  • presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body will be excluded as they will be unable to have a MRI scan.
  • premenopausal women will be excluded due to the unknown risk of MRIs during pregnancy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Toronto Western Hospital, University Health Network

Toronto, Ontario, M5T 2S8, Canada

Location

MeSH Terms

Conditions

Alzheimer DiseaseParkinson DiseaseFrontotemporal Lobar Degeneration

Interventions

Observation

Condition Hierarchy (Ancestors)

DementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental DisordersParkinsonian DisordersBasal Ganglia DiseasesMovement DisordersSynucleinopathiesTDP-43 ProteinopathiesProteostasis DeficienciesMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

MethodsInvestigative Techniques

Study Officials

  • Maria C Tartaglia, M.D.

    Toronto Western Hospital, UHN; Tanz CRND

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

September 23, 2016

First Posted

November 16, 2016

Study Start

January 1, 2013

Primary Completion

August 16, 2016

Study Completion

August 16, 2016

Last Updated

December 18, 2024

Record last verified: 2019-04

Data Sharing

IPD Sharing
Will not share

Locations